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Abstract
Blindness is a devastating situation, and one of the common causes is corneal blindness. 
Corneal transplantation is the standard treatment for the corneal blindness. The lack of 
human donors demands the exploration of alternative treatments such as corneal xeno‐
transplantation and bioengineered corneas. We review the researches regarding immu‐
nological and physio‐anatomical barriers of corneal xenotransplantation, recent progress 
of corneal xenotransplantation in nonhuman primate studies, and updates of regulatory 
guidelines to conduct clinical trials for corneal xenotransplantation. The current develop‐
ment of genetically‐engineered and gene‐editing technologies suggests that the promise 
much for the field of xenotransplantation. A clinical trial of xenotransplantation using a 
cellular porcine corneal stroma has already been conducted; however, safety concerns 
have not been reported so far. With regard to the regulatory aspects and preclinical effi‐
cacies, corneal xenotransplantation has become one of the clinically realistic options as 
human substitutes and progress in recent research is promising to advance corneal xeno‐
transplantation field.
Keywords: cornea, clinical trial, nonhuman primate, regulatory guidelines, transplantation, 
xenotransplantation
1. Introduction
Blindness is a devastating situation with an estimated 39 million cases worldwide, and one 
of the common causes is corneal blindness [1]. Corneal transplantation is the standard treat‐
ment for the corneal blindness. According to “Cost‐benefit analysis of corneal transplant,” 
which had been reported by Eye Bank Association of America and the Lewin group in 2013, 
the net lifetime benefit from the transplantation was estimated at $118,000, whereas the med‐
ical cost of the transplant was $16,500 [2]. However, supply of the donor cornea cannot meet 
the demand in developing countries, and in near future, the number of the eligible cornea 
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will be reduced in the aged societies of the developed countries [1, 3, 4]. Another reason 
to seek a substitute for allograft is that ethical concerns about organ trafficking [2, 5]. The 
lack of human donors and the ethical concerns regarding the human organ trafficking drive 
the need to explore alternative treatments such as corneal xenotransplantation and bioengi‐
neered corneas [2, 6–12]. When a survey was conducted through a telephonic interview to 
assess how corneal xenotransplantation will be perceived by the society, 42.4% of the indi‐
viduals in the wait‐list for corneal allotransplantation expressed favorable views on corneal 
xenotransplantation [13].
Cornea is considered applicable as a xenograft, because the eye is regarded as an immune‐
privileged site. Surprisingly, Dr. Kissam was the first one who conducted pig‐to‐human 
corneal xenotransplantation in 1844, although the pig cornea did not survive [14]. Current 
progress in genetically engineered (GE) pigs and development in gene editing made by 
clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 technology have 
made xenotransplantation a possible option for human application [15–21]. Recent advances 
in corneal xenotransplantation through the success in primate studies and the establishment 
of international regulatory guidelines have brought us a step closer to apply xenograft in 
clinical trials [22–25]. In fact, clinical trial of lamellar corneal transplantation using a decellu‐
larized porcine graft had been already conducted in human subjects in China to treat fungal 
ulcers [26].
This chapter reviews the current knowledge of immunological and physiological barriers 
of corneal xenotransplantation, recent progress of corneal xenotransplantation in animal 
studies, and updates of regulatory guidelines in order to conduct clinical trials of corneal 
xenotransplantation.
2. Anatomy and physiology in corneal transplantation
A cornea is an avascular and transparent collagenous tissue with a critical role in vision by 
transmitting and refracting a light in order to focus the light on the macula. Adult human 
cornea measures 11–12 mm horizontally and 9–11 mm vertically [27]. It is approximately 
500–550 μm thick in the center and 700 μm thick in the periphery [27]. The refractive power 
of the cornea is 40–44 diopters [27].
The cornea consists of three different cellular layers and two interfaces; the epithelial cell 
layer, Bowman’s layer (interface), the stroma containing keratocytes (fibroblasts), Descemet’s 
membrane (interface), and the endothelial cell layer (Figure 1) [27]. The thickness of the cor‐
neal epithelial layer is approximately 50 μm. Stem cells of the epithelium reside in the limbus, 
which is located in the peripheral junction between the cornea and the conjunctiva [27]. The 
stroma constitutes the largest portion, accounting for more than 90% of the total corneal thick‐
ness [27]. The uniform arrangement and continuous slow turn‐over of the collagen fibers by 
keratocytes are essential for corneal transparency [27]. A single layer of corneal endothelial 
cells covers the posterior surface of Descemet’s membrane, and it keeps the cornea transpar‐
ent by actively pumping out the water from the stroma using Na+‐ and K+‐dependent ATPase 
against imbibition pressure [27].
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The cornea is one of the few tissues in the body that enjoy immune‐privileged status by pas‐
sively ignoring or actively modulating immunological reactions [28, 29]. Normal and healthy 
cornea is devoid of vessels and lymphatic channels, thereby shielding it from immune‐medi‐
ated attacks by preventing transport of antigens and antigen‐presenting cells and thus attenu‐
ating the access of immune cells to the graft [28, 29]. Weak or absence of expression of major 
histocompatibility complex (MHC) class I and II antigens on the corneal cells is also related to 
the immune privilege of the cornea [29]. In addition, the cornea expresses various cell mem‐
brane‐bound or soluble immunomodulatory molecules such as Fas ligand (FasL, CD95L), com‐
plement regulatory proteins (CRPs), tumor necrosis factor (TNF)‐related apoptosis‐inducing 
ligand (TRAIL), programmed death‐ligand 1 (PD‐L1), and MHC‐Ib that are capable of sup‐
pressing immune cells [29]. Interestingly, eye has a unique immune suppression mechanism 
called anterior chamber‐associated immune deviation (ACAID) [29]. In corneal transplanta‐
tion, the donor allografts are directly contacted with the AC to induce ACAID, a distinctive 
systemic immune response to alloantigen [28]. ACAID is an active process that induces anti‐
gen‐specific CD4+ and CD8+ T regulatory cells (Tregs) capable of suppressing cellular immune 
Figure 1. Normal anatomy of the cornea and schematic figures of the different types of the keratoplasties. (A) Normal 
histology of a rabbit cornea in hematoxylin and eosin staining. (B) Schematic figure of a normal cornea which consists 
of three different cellular layers and two interfaces. (C) Penetrating keratoplasty (PK); a procedure of full thickness 
replacement of the cornea. (D) Anterior lamellar keratoplasty (ALK); a procedure of partial thickness replacement of 
the anterior cornea. (E) Deep anterior lamellar keratoplasty (DALK); a procedure of almost the full thickness of stromal 
layers except Descemet’s membrane. (F) Endothelial keratoplasty (EK); a procedure of replacement of the corneal 
endothelium including Descemet’s membrane or posterior stroma.
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responses and protecting a graft from immune rejection in transplantation [29]. However, any 
infectious or inflammatory events may break down the immunological privilege of the cornea.
The history of corneal transplantation using allografts and xenografts dates back to more 
than two centuries [3]. Penetrating keratoplasty (PK), a procedure of full thickness replace‐
ment of the cornea, has been used as the dominant procedure worldwide [3]. It is a successful 
method for most causes of corneal blindness. Lamellar transplantation surgery, that selec‐
tively replaces only diseased layers of the cornea, consists of anterior lamellar keratoplasty 
(ALK) and deep anterior lamellar keratoplasty (DALK) [3]. ALK usually replaces partial 
thickness of the anterior stromal layers and it may induce interface haze between the graft 
and the recipient corneal stroma. DALK replaces almost the full thickness of stromal layers 
except Descemet’s membrane and endothelial cell layer without inducing interface haze. Both 
procedures can be applied to patients who have a corneal opacity with an intact endothelial 
cell layer, and they can eliminate the risk of endothelial rejection [3]. Endothelial keratoplasty 
(EK) can selectively replace the corneal endothelium in patients with endothelial disease. 
Rejection risk in PK is higher rather than that in ALK/DLAK or EK [3]. Different types of 
keratoplasties are schematically shown in Figure 1.
3. Immunological barriers of corneal xenotransplantation
Although an eye is an immune‐privileged site, the innate, humoral, and cellular immune 
responses are involved in corneal allograft rejection. These immune reactions also happen in 
corneal xenograft rejection associated with pig antigens. Galactose‐alpha‐1,3‐galactose (e.g. 
αGal) to which human natural Ig M antibodies are reactive  is constantly expressed on porcine 
cells. This is a critical obstacle to overcome hyperacute xenogeneic rejection in most organ 
transplantation [30]. Therefore, the distribution of porcine antigens (e.g., αGal, non‐Gal) in the 
cornea has been investigated. It has been found that wild type (WT) porcine cornea expresses 
αGal mostly in the anterior stromal keratocytes in immunohistochemical or immunofluores‐
cent staining [31, 32]. In vitro culture, αGal expression appears on both WT porcine endothe‐
lial cells and keratocytes [32]. Based on mass spectrometry, sialylated N‐glycans have been 
identified from both WT porcine corneal endothelial cells and keratocytes [33]. As non‐Gal 
antigens, N‐glycolylneuraminic acid (NeuGc) as well as N‐acetyl sialic acid (NeuAc) are also 
identified in both WT corneal endothelial cells and keratocytes [33]. Since α1,3‐galactosyl‐
transferase gene‐knockout (GTKO) pigs that do not express the Gal epitopes have been made 
[15, 34], the feasibility of GTKO pigs is investigated for the corneal xenograft. In immuno‐
fluorescent staining, strong expression of NeuGc has been found in all layers of both WT and 
GTKO pig corneas [35]. That is to say, both αGal and non‐Gal epitopes are widely expressed 
in WT cornea, whereas antigenic epitopes such as non‐Gal are still expressed in GTKO cornea.
In vitro study has shown that IgG antibody binding affinities to the cornea or the T cell responses 
of GTKO pigs are weaker than those of WT pig corneas [35, 36]. NeuGc is a major target of human 
antibodies, but not a target of nonhuman primate (NHP) antibodies [37, 38]. The absence of 
αGal or NeuGc on porcine peripheral blood mononuclear cells or corneal cells can significantly 
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decrease human antibody binding significantly in vitro [39, 40]. However, when immune reac‐
tions are compared between GTKO/hCD46 and GTKO/hCD46/NeuGc KO pigs, the strength of 
the human T‐cell proliferative response to GTKO/hCD46/NeuGc KO pig cells is similar to that 
to GTKO/hCD46 pig cells. The absence of NeuGc expression on GTKO/hCD46 pig cells does not 
diminish human platelet aggregation or decreases the instant blood‐mediated inflammatory reac‐
tion (IBMIR) to pig cells [41]. In an NHP study, GT KO/CD46 pig corneas are not associated with 
prolongation of the graft survival or a reduced antibody response compared with WT pig corneas 
[42]. Taken together, it remains doubtful whether the absence of αGal or NeuGc expression on 
cornea of the GE pigs might have an advantage over WT cornea in in vivo xenotransplantation.
Major histocompatibility complex (MHC) antigens play important roles in corneal allotrans‐
plantation [43–45]. Therefore, MHC antigens might have roles in corneal xenotransplantation 
as in other organ xenotransplantations [46, 47]. In fact, human antiporcine T cell response 
and binding property of IgG HLA‐specific antibodies to pig lymphocytes are similar to an 
allogeneic responses with both direct and indirect pathways of recognition in the human 
antiporcine MHC class II responses being functionally intact [48–50]. In DNA microarray, 
MHC‐A has been expressed in both WT porcine corneal keratocytes and endothelial cells [51]. 
Genetically‐engineered Class I MHC knockout pigs have reduced levels of CD4−CD8+ T cells in 
peripheral blood [52]. Modulation of swine MHC by transferring human HLA DPw0401 can 
reduce human‐to‐pig cellular response, in vitro [53]. Human dominant‐negative class II trans‐
activator (CIITA‐DN) transgenic pigs that can suppress swine leukocyte antigen (SLA) class 
II expression have been found to have reduced human T cell response, in vitro [54]. Although 
MHC‐related immune response is evidently important in xenotransplantation, in vitro and in 
vivo immune responses against porcine MHCs in corneal xenotransplantation have not been 
published yet.
An unmodified cellular porcine cornea is defined as a xenotransplant medicinal product, while 
a decellularized porcine cornea is defined as a medical device [25]. As a medical device, por‐
cine decellularized cornea can be produced in various ways to reduce immunogenicity [55–58]. 
Decellularized porcine cornea has an advantage on the survival of the graft by reducing immune 
responses in different animal models as well as in human clinical study [23, 26, 56, 57, 59, 60].
4. Rejection mechanism in corneal xenotransplantation through various 
in vivo animal models
In corneal allotransplantation, a CD4+ T cell‐mediated reaction is primarily involved in graft 
rejection [8, 61–63], while CD8+ T cell‐ and complement‐mediated reactions are partially 
involved in allograft rejection [64–67].
Rejection mechanisms of corneal xenotransplantation have been investigated using various 
animal models (Table 1) [8, 23, 24, 42, 68–76]. The main rejection mechanism seems to be 
different depending on the animal model used. Unlike xenotransplantation of the vascular 
organs, hyperacute rejection (minutes to hours) is not presented in all corneal xenotransplan‐
tation models [4, 8].
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In Lewis rat‐to‐guinea pig corneal transplantation, the mean survival time of corneal xenografts 
has been reported to be 8 days with IgM and IgG xenoantibody production after pre‐sensitization 
[68]. In Guinea pig‐to‐rat model, the mean survival time of corneal xenografts is reported to be 7 
days with a IgG deposition and infiltration of T cells, neutrophils, and macrophages in the graft 
[69]. In guinea pig‐to‐mouse corneal xenotransplantation, the median survival time is 9–16 days 
in wild types, whereas the survival time is extended in mice deficient in the CD4, C3, or MHC 
class II gene, suggesting that CD4+ T cells, complement, and host antigen‐presenting cells might 
contribute to graft rejection [70, 71]. In Lewis rat‐to‐mice corneal xenotransplantation, survival 
time (mean survival time of 44.1 days) of xenograft is found to be longer after treatment with 
antiCD4 antibody compared to that of the control (mean survival of 9.4 days). However, xeno‐
grafts treated with antiCD4 antibody are rapidly rejected by antibody‐containing serum (mean 
survival of 21.5 days) [72]. In pig‐to‐mouse corneal xenotransplantation, median survival time is 
9.0 days with macrophages and CD4+ T cells being found in rejected grafts in WT mice, and the 
survival time is extended in severe combined immunodeficiency (SCID) mice [73]. Natural killer 
(NK) cells are not involved in the xenogeneic rejection in this model [73]. In pig‐to‐mouse corneal 
xenotransplantation, complement depletion has prolonged the survival of xenograft, showing 
deposition of IgG and IgM in rejected grafts [74]. In pig‐to‐GTKO mouse corneal xenotransplan‐
tation, gradual increase of IgG αGal antibody is evident suggesting that αGal might affect the 
long‐term survival of pig corneal xenografts through antibody‐mediated reactions [75].
In pig‐to‐nonhuman primate (NHP) corneal xenotransplantation, grafts are not hyperacutely 
rejected, regardless of pig genotypes [7]. In WT pig‐to‐NHP corneal xenotransplantation, 
Models Median survival (days) Proposed rejection mechanism
Lewis rat‐to‐guinea pig [68] 8 IgM and IgG xenoantibody
Guinea pig‐to‐rat [69] 7 T cell, neutrophil, macrophage, Ig G
Guinea pig‐to‐mouse [70, 71] 9–16 CD4+ T cell, complement, MHC class II
Lewis rat‐to‐mouse [72] 9.4 CD4+ T cell, antibody
Pig‐to‐mouse [73, 74] 9.0–9.4 CD4+ T cell, macrophage, complement
Pig‐to‐GTKO mouse [75] 9.0 IgG αGal antibody, CD4+ and CD8+ T 
cell, macrophage
WT pig‐to‐NHP [23, 24] 26*–189.8** CD4+ or CD8+ T cell, macrophage, B 
cell, IgG/IgM antibody, complement
GTKO/CD46 pig‐to‐ NHP [42] 104 CD3+ T cell, non‐Gal pig antibody
hCTLA4‐Ig pig‐to‐NHP [76] 70.3 Macrophage, CD3+CD4+ T cell, CD79+ 
B cell
GTKO, α1,3‐galactosyltransferase gene‐knockout; WT, wild type; NHP, nonhuman primate; CD46, membrane cofactor 
protein (MCP).
*Survival of full‐thickness keratoplasty (PKP).
**Survival of anterior lamellar keratoplasty (ALK).
Table 1. Rejection mechanisms of the corneal xenotransplantation in various animal models.
Xenotransplantation - New Insights30
infiltrations of CD4+ or CD8+ T cells, macrophages, and B cells and deposits IgG/IgM and C3c 
have been observed in rejected grafts [23, 24]. It indicates that both the cellular and humoral 
responses are involved in WT corneal xenograft rejection of NHP models as in allograft rejec‐
tion. In GT KO/CD46 (human complementary regulatory protein) pig‐to‐NHP corneal xeno‐
transplantation, CD3+ T lymphocytes still infiltrate in the graft accompanied by increased 
non‐Gal pig antibodies in the blood [42]. Cell infiltration in rejected hCTLA4Ig transgenic 
grafts is mainly composed of macrophages with CD3+, CD4+ T, and CD79+ B cells to a lesser 
extent than those in WT types of grafts [76]. It indicates that T cell‐ and antibody‐mediated 
reactions cannot be exempted even in GE pig grafts.
5. Anatomical barriers in corneal xenotransplantation
To restore a vision in corneal xenotransplantation as a functional success, anatomical (e.g., 
diameter, thickness, and tensile strength), physiological (e.g., cellular behaviors), and opti‐
cal (e.g., refractive power for light to focus on the retina) properties of the substitute cornea 
should be similar to those of a human cornea. In this regard, WT or GTKO pig cornea is con‐
sidered as a potential alternative to human cornea (Table 2) [4, 7, 77–86].
A major anatomical barrier in corneal xenotransplantation is the difference in corneal thick‐
ness between the human recipient and the pig donor. Pig corneal thickness and endothelial 
cell density are dependent on the age and the breed as shown in Table 2 [7, 77–79, 81–83]. 
Pig central corneas are thicker (659–995 μm) than human central corneas (average; 536 μm). 
The donor thickness should be in the range so that peripheral edges of the cornea between 
donor and recipient can be appropriately approximated. Unlike human cornea with center 
to peripheral thickness difference by 150–250 μm, there is no significant difference in the 
thickness between central (666 μm) and peripheral locations (657–714 μm) of pig cornea [81]. 
Consequently, a pig cornea whose central thickness is thicker than in human is considered 
applicable in human in surgical aspect. However, no paper has documented that pig corneal 
graft with a central thickness of more than 950–1000 μm is capable of being transplanted up 
to date. Tensile strength of the pig cornea is similar to that of the human cornea which is oper‐
able for corneal transplantation, although stress‐relaxation of the pig cornea is significantly 
lower than that of the human cornea [4, 84]. Differences in stress‐relaxation do not affect the 
long‐term mechanical maintenance of the graft in NHP studies. Optical power of the pig cor‐
nea has been found to be comparable to that of the human cornea [82, 83, 85].
The cornea can maintain transparency by functionally intact corneal endothelial cells. 
Therefore, endothelial density and proliferative potential in the endothelial cells of the pig 
cornea should be similar to those of human cornea. The proliferative potentials of pig and 
human endothelial cells are similar to each other [77, 79]. Endothelial cell density of the pig 
cornea is decreased depending on age, as similar to that of aged human [77–79, 86]. However, 
the age‐dependent decrease of endothelial cell density in GE pigs (1714.0 ± 19.2 mm−2 in 
20–25 months old) is higher than that in WT pigs (2130.2 ± 193.7 mm−2 in 42 months old) 
[78]. Considering that more than 2200 mm−2 ofthe endothelial cell density is preferred for 
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Parameters and breed of the pig Pig Human Mean pig age (months)
Central corneal thickness (μm)
GE pig (Revivicor, 
Blacksburg, VA)
659 [78] 536 [80] 1.5
WT Danish Landrace 
pig (Lars Jonsson Lynge, 
Denmark)
666 [81] 3.5
WT pig (Wally Whippo,  
Enon Valley, PA)
775 [78] 5–10
WT SNU miniature pig 
(Seoul, Korea)
833 [77] 42
Yorkshire pig (Seoul, 
Korea)
867 [82] 4
GE pig (Revivicor, 
Blacksburg, VA)
868 [78] 15
Sus scrofa domestica 877 [83] 6–8
GE pig (Revivicor, 
Blacksburg, VA)
914 [78] 20–25
WT pig (Wally Whippo,  
Enon Valley, PA)
995 [78] 42
Tensile strength (MPa) [84] 3.70 3.81 NA
Stress‐relaxation pattern*; P 
(×100) [84]
64.6a 85.6 NA
Stress‐relaxation pattern*; 
K (−) [84]
0.0553a 0.0165 NA
Corneal power (Diopter) 40.2 [82, 83] 43.7 [85] 4–8
Endothelial cell density (/mm2)
WT pig (Wally Whippo,  
Enon Valley, PA)
3094 [78] 2720 [86] 5–10
GE pig (Revivicor, 
Blacksburg, VA)
3022 [78] 15
WT SNU miniature pig 
(Seoul, Korea)
2625 [77] 42
WT pig (Wally Whippo,  
Enon Valley, PA)
2130 [78] 42
GE pig (Revivicor, 
Blacksburg, VA)
1714 [78] 20–25
The data present average of the parameters.
WT, Wild‐type; GE; genetically engineered; NA, not available data.
*P is the value of G (t) at the end of the stress‐relaxation test; K is the slope of fitted G (t)‐ln t line.
ap < 0.01 compared with Stress‐relaxation pattern in human.
Table 2. Anatomical, physiological, and optical properties of the pig cornea compared to those of adult human cornea.
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a donation, the age of the pig as a donor should be limited in accordance with endothelial 
cell density. The age limitation of GE pigs might be different from that of WT pigs. Unlike 
type‐dependent differences of endothelial cell density (WT versus GE), the preservation time‐
dependent decrease of endothelial cell density in WT pig cornea is not different from that in 
human cornea [77]. The preservation time‐dependent decrease of endothelial cell density in 
GE pig cornea is not reported.
6. Efficacy of corneal xenotransplantation and current progress in in vivo 
animal studies
Survival of a corneal allograft or xenograft is affected by immunologic reaction, graft size, the 
presence of corneal endothelial cells, and the hierarchical discordancy between the donor and 
the recipient [87–92]. Therefore, we should compare the survival time of xenografts depend‐
ing on the various animal models in consideration with the aforementioned risk factors.
Reported results on the survival time of different types of the pig grafts in various animal models 
are shown in Tables 3 and 4. Outcome for small and medium sized animal models is shown in 
Table 3. Decellularized graft survives longer than fresh grafts, and anterior lamellar partial thick‐
ness graft without including the endothelial cell layer survives longer than posterior lamellar or 
full thickness graft that includes the endothelial cell layer (Table 3) [56, 57, 60, 73, 93–95].
Type of pig donor Recipient Graft size (mm) Graft thickness Median survival (days)
Fresh C57BL/6 mice 3.0 Posterior lamellae+ 9.0 [73]
Fresh BALB/C mice 3.0 Posterior lamellae+ 9.0 [73]
Fresh Sprague‐Dawley rats 6.0 Posterior lamellae+ 9.3 [93]
Fresh Sprague Dawley rats 2.0 Anterior lamellae 14.0 [94]
Decellularizedς Sprague Dawley rats 2.0 Anterior lamellae 28.0 [94]
Fresh Rabbits 7.0 Anterior lamellae 29.1 [95]
Fresh Rabbits 7.0 Full thickness 16.8 [95]
Decellularized* Rabbits 8.0 Anterior lamellae >180 [57]
Decellularizedξξ Rabbits 6.3 Anterior lamellae 84 [60]
Decellularized** Rabbits 10.0 Anterior lamellae 365 [56]
+Posterior lamellae that includes endothelial cell layer (Anterior lamellae does not include endothelial cell layer).
ςLyophilized graft.
*Treated with hypertonic saline.
ξξTreated with 200 U/ml phospholipase A2 and 0.5% sodium deoxycholate.
**Treated with sodium dodecyl sulfate.
Table 3. The median survival time of various types of the pig grafts in small‐ or medium‐sized animal models.
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Type Donor pig Recipient (number) Immunosuppression Survival (days) Reported year
ALK WT Cynomolgus (n = 6) None >30+, >30+, >30+, 75, 165, 180 2003 [31]
ALK WT Rhesus (n = 4) None >90, >90, >90, >90 2007 [22]
ALK WT Rhesus (n = 5) None 180, 15, 180, 180, 180 2011 [97]
ALK WT Rhesus (n = 4) Local and systemic steroid >398, >194, 24.5, 24.5 2011 [23]
ALK WT Macaca fascicularis (n = 4) Local steroid 9, 70, 21, 21 2014 [76]
DALK WT Rhesus (n = 5) Steroid+antiCD40 antibody >389, >382, >236, >201, >61 2017 [99]
ALK* WT Rhesus (n = 5) None 180, 180, 180, 180, 180 2011 [97]
ALK* WT Rhesus (n = 5) Local steroid 180, 180, 180, 180, 180 2011 [97]
ALK* WT Rhesus (n = 5) Local and systemic steroid >391, >265, >208, >195, 28 2011 [23]
ALK hCTLA4‐Ig 
transgenic
Macaca fascicularis (n = 4) Local steroid 21, 50, 90, 120 2014 [76]
ALK GTKO/hCD39/
hCD55/hCD59/FT
Macaca fascicularis (n = 2) Local steroid 9,34 2014 [76]
PKP WT Rhesus (n = 4) Local steroid 129, 276, 182, 144 2007 [22]
PKP WT Rhesus (n = 6) Cyclophosphamide+BMT 32, 42, 40, 34, 38, 30 2013 [98]
PKP WT Rhesus (n = 6) Cyclophosphamide 12, 18, 16, 20, 20, 20 2013 [98]
PKP WT Rhesus (n = 3) Local and systemic steroid 21, 28, 29 2015 [24]
PKP WT Rhesus (n = 4) Local and systemic steroid + 
antiCD154 antibody
>933, >243, 318, >192 2015 [24]
PKP WT Rhesus (n = 4) Local steroid 157, 28, 92, 33 2017 [42]
PKP GTKO/CD46 Rhesus (n = 4) Local steroid 128, 57, 47, 171 2017 [42]
ALK, anterior lamellar keratoplasty (partial thickness); BMT, bone marrow transplantation; DALK, deep anterior lamellar keratoplasty; FT, fucosyl transferase; GTKO, 
α1,3‐galactosyltransferase gene‐knockout; hCTLA4‐Ig, human cytoxic T‐lymphocyte‐associated antigen4‐immunoglobulin; hCD39, human ectonucleoside triphosphate 
diphosphohydrolase‐1; CD46, membrane cofactor protein (MCP); hCD55, human complement decay‐accelerating factor; hCD59, human MAC‐inhibitory protein; PKP, 
penetrating keratoplasty (full thickness).
+Sacrificed at 1 month for histology.
*Decellularized cornea.
Table 4. Current progress on clinical efficacies in pig‐to‐NHP corneal xenotransplantation from 2003 to 2017.
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Current progress on clinical efficacies in pig‐to‐NHP corneal xenotransplantation from 2003 to 
2017 is shown in Table 4 [7, 22–24, 31, 42, 76, 96–99]. Some studies have presented encouraging 
outcomes in lamellar or full‐thickness corneal xenotransplantation with or without immuno‐
suppressants. The survival time varies depending on the breed of the donor and recipients, 
immunosuppressive protocols, and types of the corneal grafts. Processed acellular corneas can 
prolong the survival time of ALK. With steroid treatment, partial thickness corneal transplanta‐
tion that does not include endothelial cell layer (ALK) shows better survival than full thickness 
corneal transplantation (PKP). GE pigs in ALK or PKP do not show significant increase of the 
survival time compared to the control. With antiCD154 treatment, PKP using WT Seoul National 
University (SNU) miniature pig has demonstrated the longest survival time in the NHP model. 
Taken together, corneal xenotransplantation using fresh pig graft still requires stronger immu‐
nosuppressant than steroid alone, regardless of the type of donor pig (WT or GE).
7. Updates on regulatory aspects of corneal xenotransplantation
In 2013, the first consensus on guidelines for clinical trials of corneal xenotransplantation has 
been established in Korea [87]. Thereafter, international consensus statement on conditions 
for undertaking clinical trials of xenocorneal transplantation has been finally published in 
International Xenotransplantation Society (IXA) in 2014 [25]. IXA consensus statements on 
conditions for clinical trials of corneal xenotransplantation include the followings; (1) ethical 
requirement, (2) quality control of source pigs, (3) quality control of pig corneal products, (4) 
preclinical efficacy and safety data that are required to justify a clinical trial, (5) strategies to 
prevent porcine endogenous virus transmission (PERV) transmission, and (6) patient selec‐
tion and informed consent.
Key ethical requirements for clinical trials of corneal xenotransplantation are essentially identi‐
cal to those required in other areas of clinical trials. These guidelines adhere to the basic ethical 
principles for clinical trials of islet xenotransplantation established by the Ethics Committee of 
the IXA and the Changsha Communique of the World Health Organization [25, 100]. Regulatory 
guidelines for pig sources and strategies to prevent porcine endogenous virus transmission 
(PERV) are basically the same as those for clinical trials of islet xenotransplantation [101–103].
Guidelines for corneal‐specific issues have been intensively discussed on the procurement of 
porcine corneal products, preclinical efficacy, and safety data to justify initiation of a clinical 
trial, and inclusion criteria of the subjects. In order to be enrolled, the subject must meet the 
following criteria; (1) must be diagnosed with legal blindness as defined by the American 
Medical Association and the United States Congress as best corrected visual acuity of 20/200 
or less in the better eye, (2) must be diagnosed with a corneal blindness that can be only cured 
with a corneal transplantation, (3) must not have timely access to receive corneal allotrans‐
plantation, (4) must be over the legal age, (5) must not be pregnant, must not plan to become 
pregnant, and must not be breast feeding, and (6) should be highly compliant. Keratoconus 
should be excluded due to the excellent allograft survival and younger age of the sub‐
ject. Guideline for visual acuity can be exempted in a subject who requires an emergency 
Current Progress in Corneal Xenotransplantation
http://dx.doi.org/10.5772/intechopen.69144
 operation for actual or impending corneal perforation. Regarding adequate procurement of 
the corneal xeno‐product, the guidelines of the European Eye Bank Association (EEBA) on 
the preparation of human corneal tissue should be adopted under provision that laboratory 
tests have confirmed that biological properties of the preserved pig cornea based on EEBA 
guidelines are comparable to those of the preserved human cornea. To prove preclinical effi‐
cacy, NHP data that the pig cornea xenograft should survive for more than 6 months in five 
of eight consecutive NHPs are required (ideally for 12 months in one or two successful cases). 
Compared to the 5‐year survival rate (70–80%) of the islet allotransplantation, mean 5‐year 
survival rate of corneal allotransplantation among the various corneal diseases is similar to 
each other (70–80%) [104–106]. Therefore, the same preclinical efficacy that has been accepted 
for islet xenotransplantation can be applied to corneal xenotransplantation with provisional 
condition that patient who is diagnosed as keratoconus must be excluded.
In 2016, the IXA consensus statement on conditions for undertaking clinical trials of porcine 
islet products has been revised for the first time [107–114]. New or under‐appreciated topics 
have been discussed and updated regarding regulatory framework, genetic modification of 
the source pig, recipient monitoring for preventing disease transmission, patient selection, 
porcine islet product manufacturing, and quality control of source pigs. To undertake clini‐
cal trials of corneal xenotransplantation, under‐appreciated topics as follows should also be 
addressed and revised [2]. (1) In source pigs, PERV‐C negative donor pigs should be con‐
sidered preferable, and donor pig selection criteria should be primarily based on low PERV 
expression levels and the lack of infectivity. (2) Clinical trial protocols using GE pig products 
also need to be assessed on a case‐by‐case basis. (3) For preclinical efficacy in corneal xeno‐
transplantation, the finding that survival in four of six (or five of eight) consecutive NHP 
experiments may be sufficient to indicate potential success of a clinical trial that is similar to 
those in islet xenotransplantation. (4) Clinically relevant microorganisms should be included 
in pig screening programs. (5) When microorganisms are confirmed to be absent in the donor 
pig by sensitive microbiological examination, recipients need not to be monitored. (6) Life‐
long surveillance for PERV should be adjusted based on the clinical sign and the laboratory 
test if the subjects do not show any suspicious sign of PERV infection by sensitive laboratory 
examination for 2 years. In a clinical trial of islet cell xenotransplantation using microen‐
capsulated pig islets, PERV DNA and PERV RNA are not detected in peripheral blood up 
to 113 weeks by real‐time RT‐PCR [115]. In this clinical trial, the subjects were followed‐up 
for two years. If the risk of PERV transmission is proved to be negligent, follow‐up time 
should be adjusted accordingly. Given that substantial scientific progress has been made in 
islet xenotransplantation and cornea field, the international consensus statement on corneal 
xenotransplantation is expected to be updated regarding these under‐appreciated issues.
8. Future perspectives
Due to progresses made in immunosuppressive protocols, the availability of GE pigs, and 
appropriate guidelines for clinical trials, corneal xenotransplantation using pig cornea might 
be a feasible option to solve the shortage of donor corneas in the future. Decellularized porcine 
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graft also appears to be efficient in a clinical trial. Results of recent experiments of the corneal 
xenotransplantation in NHP models using cellularized pig grafts are encouraging, and it helps 
us decide whether we should keep developing xeno‐related products of cornea. With better 
understanding on the antigenicity of pig cornea and the rejection mechanism involved in corneal 
xenotransplantation, optimized and standardized immunosuppression should be established 
before conducting a human clinical trial. As for fresh corneal grafts from GE pigs, the further 
experiments need to be performed to verify their efficacies as substitutes for human corneas.
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